{
  "schema_version": 1,
  "generated_at": "2026-05-20T10:39:12Z",
  "ticker": "NTLA",
  "headlines": [
    {
      "title": "Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?",
      "publisher": "Zacks",
      "published_at": "2026-05-19T15:53:00+00:00",
      "age_hours": 18.77004920111111,
      "link": "https://finance.yahoo.com/sectors/healthcare/articles/intellias-pipeline-push-drive-long-155300020.html",
      "summary": "NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth."
    },
    {
      "title": "Intellia Therapeutics, Inc. (NASDAQ:NTLA) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year",
      "publisher": "Simply Wall St.",
      "published_at": "2026-05-14T12:54:40+00:00",
      "age_hours": 141.7422714261111,
      "link": "https://finance.yahoo.com/sectors/healthcare/articles/intellia-therapeutics-inc-nasdaq-ntla-125440126.html",
      "summary": "Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) investors will be delighted, with the company turning in some strong..."
    },
    {
      "title": "High Growth Tech Stocks In The US For May 2026",
      "publisher": "Simply Wall St.",
      "published_at": "2026-05-13T11:38:06+00:00",
      "age_hours": 167.01838253916668,
      "link": "https://finance.yahoo.com/news/high-growth-tech-stocks-us-113806041.html",
      "summary": "The United States market has experienced a 1.5% increase over the last week and a substantial 26% rise over the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to capitalize on these favorable conditions."
    },
    {
      "title": "NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus",
      "publisher": "Zacks",
      "published_at": "2026-05-12T15:44:00+00:00",
      "age_hours": 186.92004920777777,
      "link": "https://finance.yahoo.com/sectors/healthcare/articles/ntla-q1-earnings-beat-estimates-154400643.html",
      "summary": "Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data."
    },
    {
      "title": "Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates",
      "publisher": "Zacks",
      "published_at": "2026-05-11T12:40:02+00:00",
      "age_hours": 213.98616032055557,
      "link": "https://finance.yahoo.com/sectors/healthcare/articles/intellia-therapeutics-inc-ntla-reports-124002615.html",
      "summary": "Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +11.60% and -3.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?"
    }
  ]
}